Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Analysis of Expenditure in Multiple Sclerosis Disease Modifying Therapies Evolution Between 2004-2013 in Spain.
Boosting CNS axon regeneration by circumventing limitations of natural cytokine signaling.
Factors Associated with Caregiver's Burden in Relapsing-Remitting Multiple Sclerosis and Satisfaction with Current Therapies. MS-Feeling Study.
Best Practices and Key Challenges in Cost-Effectiveness Modelling of Multiple Sclerosis Therapies.
Rapidly progressive cerebellar ataxia in West Wales.
25 Hydroxyvitamin D and Cytokines in Multiple Sclerosis.
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Static posturography across the EDSS scale in people with multiple sclerosis: a cross sectional study.
The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.
Sodium intake is associated with increased disease activity in multiple sclerosis.
Systematic Review and Critique of Health Economic Models on Relapsing-Remitting Multiple Sclerosis in the UK.
Moody microbes or fecal phrenology: what do we know about the microbiota-gut-brain axis?
Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset.
Multiple sclerosis: Bigger brains resist disability in MS.
Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3.
Co-occurrence of multiple sclerosis and Parkinson disease.
[The biological role of sulfatides].
All relapsing multiple sclerosis patients should be seen in specialist clinics - NO.
The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55.
Efficacy of hematopoietic stem cell formultiple sclerosis, an evidence based meta-analysis.
Evaluation of chronic inflammatory demyelinating polyneuropathy: 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI).
A review of Neuropharmacology Effects of Nigella sativa and Its Main Component, Thymoquinone.
Understanding walking activity in multiple sclerosis: step count, walking intensity and uninterrupted walking activity duration related to degree of disability.
The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis.
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »